Marino A, Pulvirenti S, Campanella E, Stracquadanio S, Ceccarelli M, Micali C, Tina LG, Di Dio G, Stefani S, Cacopardo B, et al. Ceftazidime-Avibactam treatment for Klebsiella Pneumoniae bacteremia in preterm infants in NICU: A clinical experience. Antibiot (Basel). 2023;12:1169. https://doi.org/10.3390/antibiotics12071169.

Article  CAS  Google Scholar 

Tumbarello M, Raffaelli F, Giannella M, De Pascale G, Cascio A, De Rosa FG, Cattelan AM, Oliva A, Saracino A, Bassetti M, et al. Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study. Open Forum Infect Dis. 2024;11:ofae273. https://doi.org/10.1093/ofid/ofae273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giacobbe DR, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, et al. Use of colistin in adult patients: A Cross-Sectional study. J Glob Antimicrob Resist. 2020;20:43–9. https://doi.org/10.1016/j.jgar.2019.06.009.

Article  PubMed  Google Scholar 

Giacobbe DR, Marelli C, Cattardico G, Fanelli C, Signori A, Di Meco G, Di Pilato V, Mikulska M, Mazzitelli M, Cattelan AM, et al. Mortality in KPC-Producing Klebsiella Pneumoniae bloodstream infections: A changing landscape. J Antimicrob Chemother. 2023;78:2505–14. https://doi.org/10.1093/jac/dkad262.

Article  CAS  PubMed  Google Scholar 

Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788. https://doi.org/10.1001/jama.2018.0438.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaibani P, Lombardo D, Bussini L, Bovo F, Munari B, Giannella M, Bartoletti M, Viale P, Lazzarotto T, Ambretti S. Epidemiology of meropenem/vaborbactam resistance in KPC-Producing Klebsiella Pneumoniae causing bloodstream infections in Northern italy, 2018. Antibiotics. 2021;10:536. https://doi.org/10.3390/antibiotics10050536.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee Y-L, Ko W-C, Hsueh P-R. Geographic patterns of global isolates of Carbapenem-Resistant Klebsiella Pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: results from the antimicrobial testing leadership and surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2022;60:106679. https://doi.org/10.1016/j.ijantimicag.2022.106679.

Article  CAS  PubMed  Google Scholar 

Marino A, Campanella E, Stracquadanio S, Calvo M, Migliorisi G, Nicolosi A, Cosentino F, Marletta S, Spampinato S, Prestifilippo P, et al. Ceftazidime/Avibactam and meropenem/vaborbactam for the management of enterobacterales infections: A narrative review, clinical considerations, and expert opinion. Antibiot (Basel). 2023;12:1521. https://doi.org/10.3390/antibiotics12101521.

Article  CAS  Google Scholar 

Oliva A, Volpicelli L, Di Bari S, Curtolo A, Borrazzo C, Cogliati Dezza F, Cona A, Agrenzano S, Mularoni A, Trancassini M, et al. Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-Producing Klebsiella pneumoniae: results from a multicentre retrospective study. JAC-Antimicrobial Resist. 2022;4:dlac121. https://doi.org/10.1093/jacamr/dlac121.

Article  CAS  Google Scholar 

Ackley R, Roshdy D, Meredith J, Minor S, Anderson WE, Capraro GA, Polk C. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for treatment of Carbapenem-Resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64. https://doi.org/10.1128/aac.02313-19.

Zilberberg MD, Nathanson BH, Redell MA, Sulham K, Shorr AF. Comparative outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam among adults hospitalized with an infectious syndrome in the US, 2019–2021. Antibiotics. 2025;14:29. https://doi.org/10.3390/antibiotics14010029.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8.

Article  CAS  PubMed  Google Scholar 

Moreno R, Rhodes A, Piquilloud L, Hernandez G, Takala J, Gershengorn HB, Tavares M, Coopersmith CM, Myatra SN, Singer M, et al. The sequential organ failure assessment (SOFA) score: has the time come for an update?? Crit Care. 2023;27. https://doi.org/10.1186/s13054-022-04290-9.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13:818–29.

CAS  PubMed  Google Scholar 

EU Case Definitions Available online. https://www.ecdc.europa.eu/en/all-topics/eu-case-definitions (accessed on 19 November 2024).

Jong, E. de; Oers, J.A. van; Beishuizen, A.; Vos, P.; Vermeijden, W.J.; Haas, L.E.; Loef, B.G.; Dormans, T.; Melsen, G.C. van; Kluiters, Y.C.; et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, Open-Label trial. Lancet Infect Dis. 2016;16:819–27. https://doi.org/10.1016/S1473-3099(16)00053-0.

Article  CAS  PubMed  Google Scholar 

von Dach E, Albrich WC, Brunel A-S, Prendki V, Cuvelier C, Flury D, Gayet-Ageron A, Huttner B, Kohler P, Lemmenmeier E, et al. Effect of C-Reactive Protein–Guided antibiotic treatment duration, 7-Day treatment, or 14-Day treatment on 30-Day clinical failure rate in patients with uncomplicated Gram-Negative bacteremia: A randomized clinical trial. JAMA. 2020;323:2160–9. https://doi.org/10.1001/jama.2020.6348.

Article  CAS  Google Scholar 

D’Agostino RB. Propensity score methods for Bias reduction in the comparison of a treatment to a Non-Randomized control group. Stat Med. 1998;17:2265–81. https://doi.org/10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b.

Article  PubMed  Google Scholar 

Eikenboom AM, Le Cessie S, Waernbaum I, Groenwold RHH, de Boer MGJ. Quality of conduct and reporting of propensity score methods in studies investigating the effectiveness of antimicrobial therapy. Open Forum Infect Dis. 2022;9:ofac110. https://doi.org/10.1093/ofid/ofac110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113:390–400. https://doi.org/10.1080/01621459.2016.1260466.

Article  CAS  Google Scholar 

Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–5. https://doi.org/10.1056/NEJM198707163170304.

Article  CAS  PubMed  Google Scholar 

Granger E, Watkins T, Sergeant JC, Lunt MA. Review of the use of propensity score diagnostics in papers published in High-Ranking medical journals. BMC Med Res Methodol. 2020;20:132. https://doi.org/10.1186/s12874-020-00994-0.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Kim HJ, Lonjon G, Zhu Y. Written on behalf of AME Big-Data clinical trial collaborative group balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16. https://doi.org/10.21037/atm.2018.12.10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Austin PC. Optimal caliper widths for Propensity-Score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150–61. https://doi.org/10.1002/pst.433.

Article  PubMed  Google Scholar 

Imai K, Ratkovic M. Covariate balancing propensity score. J Royal Stat Soc Ser B: Stat Methodol. 2014;76:243–63. https://doi.org/10.1111/rssb.12027.

Article  Google Scholar 

Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, Shin H, Ma Y, Keeton S, Karami S, et al. Relative performance of propensity score matching strategies for subgroup analyses. Am J Epidemiol. 2018;187:1799–807. https://doi.org/10.1093/aje/kwy049.

Article  PubMed  Google Scholar 

Ali MS, Prieto-Alhambra D, Lopes LC, Ramos D, Bispo N, Ichihara MY, Pescarini JM, Williamson E, Fiaccone RL, Barreto ML, et al. Propensity score methods in health technology assessment: principles, extended applications, and recent advances. Front Pharmacol. 2019;10. https://doi.org/10.3389/fphar.2019.00973.

VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med. 2017;167:268–74. https://doi.org/10.7326/M16-2607.

Article  PubMed  Google Scholar 

Tsioutis C, Eichel VM, Mutters NT. Transmission of Klebsiella Pneumoniae carbapenemase (KPC)-Producing Klebsiella pneumoniae: the role of infection control. J Antimicrob Chemother. 2021;76:i4–11. https://doi.org/10.1093/jac/dkaa492.

Article  CAS  PubMed  Google Scholar 

Theuretzbacher U, Carrara E, Conti M, Tacconelli E. Role of new antibiotics for KPC-Producing Klebsiella Pneumoniae. J Antimicrob Chemother. 2021;76:i47–54. https://doi.org/10.1093/jac/dkaa497.

Article  CAS  PubMed  Google Scholar 

Marino A, Stracquad